Reset, Recovery, and the New Economics at Option Care Health
Q2 2026 posts the first real signs of life post-Stelara reset, but a structural margin step-down and the emergence of white-bagging rewrite the growth algorithm.
OPCH · Earnings Call · 2026-07-29
The Reset's Reckoning
Option Care Health's second quarter of 2026 was less a growth story than proof of life. Coming off a first quarter in which the Stelara/biosimilar conversion stripped out patient population and decimated the chronic inflammatory (CID) franchise — the company's own word is "reset" — Q2 finally produced an inflection: revenue of $1.4 billion was up 7% sequentially, and adjusted EBITDA of $117.5 million was up 12% sequentially, both ahead of internal expectations. The prepared remarks were carefully hedged, but underneath sat a real first: CID patient census rose sequentially for the first time since the collapse.
Across our chronic inflammatory portfolio... we began to stabilize our portfolio coming out of the first quarter reset. And saw our second quarter patient census rise sequentially.
The recovery, however, is being built on different economics than the business that preceded it. Acute therapy grew in the high single digits, IG neuro resumed strong growth, and the rare/orphan portfolio added new programs. But Stelara and its biosimilars are now guided to "represent less than 1% of 2026 company net revenue" — a plain admission that what was once a dominant product is now a rounding error. This is the reset pressed to its conclusion: the company is growing around the loss, not replacing it. Management maintained the $55 million gross-profit headwind and the ~600 basis points of revenue headwind, and reiterated the expectation of no further headwinds in 2026 or 2027.
The contrast with the first-quarter call is stark. In April, Meenal Sethna conceded that the original plan had simply failed: "we had assumed a number of Stelara patients converting to some other therapy as part of our portfolio, and that didn't happen. So the loss of that patient is what that is." John Rademacher added that "many of those determinations and decisions really weren't made until the March time frame" — an unusually long, painful reverification cycle. That is the chasm Q2 has begun to climb out of.
A Margin Floor, Not a Ceiling
The structural problem lurking inside the recovery is that margin now depends on mix, and the mix is moving the wrong way. Gross margin has stepped down from roughly 23% in 2022 to 19.4% in Q1 2026 — a permanent degradation driven by the loss of Stelara economics and a tilt toward chronic and rare-orphan therapies that carry lower product margins than the acute franchise.
Even as acute growth (product margins north of 50%) runs high-single digits, gross margin sits at 19.4% — the floor here is structural, not cyclical.
Analysts pressed hard on this. Lisa Gill walked through the arithmetic of a roughly 8.3% EBITDA margin implied for Q3 by the sequential revenue and EBITDA guidance; management essentially accepted the math. This is why therapy mix — and the cost discipline layered on top — is doing the heavy lifting on the bottom line. Sethna was explicit that earnings are being supported by variable compensation cuts, lower SG&A (down 3% year-over-year, ~11% of revenue), and an artificial intelligence deployment aimed at nurse routing, claims, and patient onboarding — buying EBITDA growth with operational discipline rather than revenue leverage.
New Frictions, Same Playbook
Two genuinely new frictions surfaced. white bagging — the PBM practice of shipping high-cost therapies to physician offices rather than through specialty pharmacies — was raised as a potentially spreading threat beyond Stelara-class drugs. John Rademacher's reply was measured ("we have not seen a significant impact on white-bagging"), but the question itself marked the arrival of a new competitive concern layered on top of the biosimilar conversion. Separately, the CMS proposal to expand Medicare coverage for certain home infusion pumps starting in 2027 was framed as narrow and unlikely to be material — an acknowledgment that the long-hoped-for Medicare expansion remains small-bore.
The playbook is the same one that carried the company through the first quarter: discipline plus the balance sheet. Q2 saw $150 million of buybacks — nearly 5% of shares outstanding — and Sethna confirmed that guidance embeds no further buybacks beyond what has already been done. She was equally adamant that the cost actions are "not necessarily cost cuts just to cut." The scaled-up repurchase — $95 million in Q1 and $150 million in Q2 against a price-to-revenue of just 0.7x — shows aggressive capital return while the recovery is still fragile.
The stock's tape mirrors the fundamentals: a sharp ~31% drawdown into the Q1 report, then a ~21% recovery leg into Q2 — the market penalizing the reset, then tentatively rewarding the stabilization. Net leverage of 2.1x and interest coverage of 5.5x leave capacity, but the honest read of Q2 is that the floor has been hit, the recovery is real, and the margin structure plus the competitive field (now including white-bagging) is permanently different. patient census recovery is the metric that will define whether this becomes a full re-acceleration or a smaller, leaner company.